US Patent

US11077106 — Cancer treatment

Method of Use · Assigned to Janssen Pharmaceutica NV · Expires 2038-02-02 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating cancer with erdafitinib.

USPTO Abstract

The present invention provides a method for the treatment of cancer with erdafitinib.

Drugs covered by this patent

Balversa (ERDAFITINIB) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3196`	—	Balversa
`U-3196`	—	Balversa
`U-3196`	—	Balversa

Patent Metadata

Patent number: US11077106
Jurisdiction: US
Classification: Method of Use
Expires: 2038-02-02
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.